Jane A. Beebe, Ph.D. Email and Phone Number

• Lead microparticle scientist for research and development of several diagnostic assays on the Architect platform.• Transfer of these processes to overseas Manufacturing sites.• Technical lead for improvement and standardization of A280 test method across manufacturing sites. Organized Lake County multi-lab and Global Multisite studies demonstrating improved process reproducibility. • Lead scientist for analysis of electrostatic effects on antibody orientation and microparticle potency in collaboration with Molecular Binding Characterization group. Presented at Tech Review November 2010.• Abbott Women and Science (AWS) Events Committee Chair 2013, 2014• Promoted to Principal Scientist April 2013POSTERSWeber Symposium: Ruan, Q., Saldana, S.C., Beebe, J., and Tetin, S.Y. (2011) Measuring Biophysical Properties of Antibodies Coated on Microparticles.Nano Science and Technology Institute (NSTI): Aline Authors - McDowell, J., Wong, N.T., and Levine, L. Abbott Authors - Beebe, J., Horne, J., Eng, E., Bogdan, F, Harwick, L., and Schultz, P. (2010) Simplified Quantitation of Proteins at A280 Using a One-millimeter Matched Pathlength Plastic Cuvette.

On-market product support for enzyme immunoassays used for screening the blood supply. • Technical troubleshooting and implementing product/process improvements for HIV and HTLV virus enzyme immunoassays.• Led major effort to implement improvements in manufacturability of HTLV Enzyme Immunoassay (> 40 documents). Worked with Regulatory, CMG, Manufacturing and Testing to ensure compliance and executability of changes.

Core team member for many product development activities required for US launch of the PRISM platform, a chemiluminescence-based assay used for screening the blood supply. Designed, organized and executed process improvement experiments for PRISM HIV O Plus assay (successfully launched September, 2009). • Lead scientist for process to qualify the vendors of two major components used in manufacturing the assay (biotin-XX-NHS ester and Superdex column). Received Manager’s Award for this effort July 2006. • Design Verification Studies involving testing on PRISM instruments and Design Review Deliverables for product launch.

Research and Development Scientist, Biochemical Assay Group Design, development and validation of Z′-LYTE FRET-based kinase assays. Also lead scientist for research to study cancer causing mutants of the epidermal growth factor receptor (EGFR) kinase. • Z′-LYTE kinase assay new product development by designing 14 potential new synthetic peptide substrates. In collaboration with product manager 11 of these were pursued for development. • Modified a peptide substrate to improve assay dynamic range for Ser/Thr kinase substrate panel and assay kit.• Demonstrated assay could be used for profiling compounds. • Lead scientist for studies of of substrate specificity of oncogenic mutants of the EGFR kinase using fluorescence polarization (FP) assay resulting in a publication in the Journal of Biological Chemistry.• Initiated and led discussion group composed of multiple groups with an interest in biochemical assay PATENTSKlink, T. Beebe, J., Lasky, D., Kleman-Leyer, K., and Somberg, R. (2011) Kinase and Phosphatase Assays, Patent # 8,067,536.Kupcho, K.R., Vogel, K., Werner, E.A., Beebe, J.A., Klink, T.A., Lasky, D.A., Kleman-Leyer, K.M., and Somberg, R. (2009) Biomolecular Optical Probes, Patent # 7,619,059.PUBLICATIONSBeebe, J.A., Wiepz, G.J., Guadarrama, A.G., Bertics, P.J. and Burke T.J. (2003) A Carboxy Terminal Mutation of the Epidermal Growth Factor Receptor Alters Tyrosine Kinase Activity and Substrate Specificity as Measured by a Fluorescence Polarization Assay, J. Biol. Chem. 278, 26810-16816.Burke, T.J., Loniello, K.R., Beebe, J.A., and Ervin K.M. (2003) Development and Application of Fluorescence Polarization Assays in Drug Discovery, Comb. Chem. High Throughput Screen. 6, 183-194.